Summary
Intraduodenal phenylalanine administration (333 mg/min over 60 min) released endogenous cholecystokinin in healthy young subjects as demonstrated radioimmunologically and by intraduodenal bilirubin and pancreatic enzyme output. Concomitantly, there was only a small increase over basal in circulating immunoreactive-insulin and immunoreactive-C-peptide concentrations. In healthy volunteers intraduodenal infusions of saline (10 ml/min), glucose (333 mg/min) or phenylalanine (333 mg/min) were performed for 60 min when plasma glucose was clamped at approximately 8 mmol/l. Phenylalanine enhanced immunoreactive-insulin and immunoreactive-C-peptide responses three-fold more than did the same amount of glucose. Immuno-reactive gastric inhibitory polypeptide responses were small and not different after glucose and phenylalanine administration. Immunoreactive cholecystokinin was significantly stimulated to 9.4±1.4pmol/l only by intraduodenal phenylalanine. Plasma phenylalanine concentrations increased into the supraphysiological range (approximately 1.5 mmol/l). Intravenous infusions of phenylalanine achieving plasma concentrations of 1.2 mmol/l stimulated insulin secretion at elevated plasma glucose concentrations (approximately 8 mmol/l clamp experiments), but had no effect at basal plasma glucose concentrations. A small increase in cholecystokinin also was observed. Intravenous infusions of synthetic sulphated cholecystokinin-8 leading to plasma concentrations in the upper postprandial range (8–12 pmol/l) did not augment the immunoreactive-insulin or immunoreactive-C-peptide levels during hyperglycaemic clamp experiments, in the absence or presence of elevated plasma phenylalanine concentrations. It is concluded that the augmentation of the glucose-induced insulin release by intraduodenal administration of phenylalanine cannot be related to cholecystokinin release, but rather is explained by the combined effects of elevated glucose and phenylalanine concentrations. In man, cholecystokinin does not augment insulin secretion caused by moderate hyperglycaemia, elevations of phenylalanine concentrations, or combinations thereof.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Unger RH, Eisentraut AM (1969) Entero-insular axis. Arch Intern Med 123: 261–266
Creutzfeldt W, Ebert R (1986) The enteroinsular axis. In: Go VLW (ed) The exocrine pancreas: biology, pathobiology, and diseases. Raven Press, New York
Creutzfeldt W (1979) The incretin concept today. Diabetologia 16: 75–85
Creutzfeldt W, Ebert R (1985) New developments in the incretin concept. Diabetologia 28: 565–573
Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46–52
Nauck MA, Homberger E, Siegel E, Allen RC, Eaton RP, Ebert R, Creutzfeldt W (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492–498
Creutzfeldt W, Ebert R (1976) Release of gastric inhibitory polypeptide (GIP) to a test meal under normal and pathological conditions in man. Excerpta Medica International Congress Series No. 413. Diabetes. Excerpta Medica, Amsterdam
Elahi D, Andersen DK, Brown JC, Debas HT, Hershkopf RJ, Raizes GS, Tobin JD, Andres R (1979) Pancreatic α-and β-cell responses to GIP infusion in normal man. Am J Physiol 237: E185–191
Sakamoto C, Otsuki M, Ohki A, Yuu H, Yamasaki T, Baba S (1982) Glucose dependent insulintropic action of cholecystokinin and caerulein in isolated perfused rat pancreas. Endocrinol 110: 398–402
Zawalich WS, Cote SB, Diaz VA (1986) Influence of cholecystokinin on insulin output from perifused pancreatic islets. Endocrinol 119: 616–621
Szecokwa J, Lins PE, Efendic S (1982) Effects of cholecystokinin, gastric inhibitory polypeptide, and secretin on insulin and glucagon secretion in rats. Endocrinol 110: 1268–1272
Rossetti L, Shulman GI, Zawalich WS (1987) Physiological role of cholecystokinin in meal-induced insulin secretion in conscious rats: studies with L 364718, a specific inhibitor of CCK-receptor binding. Diabetes 36: 1212–1215
Hermansen K (1984) Effects of Cholecystokinin (CCK)-4, Non-sulfated CCK-8, and sulfated CCK-8 on pancreatic somatostatin, insulin, and glucagon secretion in the dog: studies in vitro. Endocrinol 114: 1770–1775
Lindkaer Jensen S, Rehfeld JF, Holst JJ, Nielsen OV, Fahrenkrug J, Schaffalitzky de Muckadell OB (1981) Secretory effects of cholecystokinins on the isolated perfused porcine pancreas. Acta Physiol Scand 111: 225–231
Sakamoto C, Goldfine ID, Roach E, Williams JA (1985) Localization of saturable binding sites in rat pancreatic islets by light and electron microscope autoradiography. Diabetes 34: 390–394
Verspohl EJ, Ammon HPT, Williams JA, Goldfine ID (1986) Evidence that cholecystokinin interacts with specific receptors and regulates insulin release in isolated rat islets of Langerhans. Diabetes 35: 38–43
Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA (1985) Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75: 1144–1152
Owyang C, Louie DS, Tatum D (1986) Feedback regulation of pancreatic enzyme secretion. Suppression of Cholecystokinin release by trypsin. J Clin Invest 77: 2042–2047
Go VLW, Hofmann AF, Summerskill WHJ (1970) Pancreozymin bioassay in man based on pancreatic enzyme secretion: potency of specific amino acids and other digestive products. J Clin Invest 49: 1558–1564
Rushakoff RJ, Goldfine ID, Carter JD, Liddle RA (1987) Physiological concentrations of cholecystokinin stimulate amino-acid induced insulin release in humans. J Clin Endocrinol Metab 65: 395–401
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214–223
Melani F, Ditschuneit H, Bartelt HM, Friedrich H, Pfeiffer EF (1965) Über die radioimmunologische Bestimmung von Insulin im Blut. Klin Wochenschr 43: 1000–1006
Cantor P (1986) Evaluation of a radioimmunoassay for cholecystokinin in human plasma. Scand J Lab Clin Invest 46: 213–221
Kuzio M, Dryburgh JR, Malloy KM, Brown JC (1974) Radioimmunoassay for gastric inhibitory polypeptide. Gastroenterol 66: 357–364
Ebert R, Illmer K, Creutzfeldt W (1979) Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterol 76: 515–523
Mayer G, Arnold R, Feurle G, Fuchs K, Ketterer H, Track NS, Creutzfeldt W (1974) Influence of feeding and sham feeding upon serum gastrin and gastric acid secretion in control subjects and duodenal ulcer patients. Scand J Gastroenetrol 9: 703–710
Jendrassik L, Graf O (1938) Vereinfachte Methoden zur Bestimmung des Blutbilirubins. Biochem Zeitschr 297: 6–15
Erlanger BF, Kokonsky N, Cohen W (1961) The preparation and properties of two new chromogenic substrates of trypsin. Arch Biochem Biophys 95: 271–278
Rick W, Stegbauer HP (1970) α-amylase-Messung der reduzierenden Gruppen. In: Bergmeyer HU (ed) Methoden der enzymatischen Analyse, Vol 1, 2nd edn. Verlag Chemie, Weinheim
Harper JF (1984) Peritz' F test: basic program of a robust multiple comparison test for statistical analysis of all differences among group means. Comput Biol Med 14: 437–445
Doberne L, Greenfield MS, Schulz B, Reaven GM (1981) Enhanced glucose utilization during prolonged glucose clamp studies. Diabetes 30: 829–835
Floyd JC, Fajans S, Conn JW, Knopf RF, Rull J (1966) Stimulation of insulin secretion by amino acids. J Clin Invest 45: 1487–1502
Floyd JC, Fajans SS, Pek S, Thiffault CA, Knopf RF, Conn JW (1970) Synergistic effect of essential amino acids and glucose upon insulin secretion in man. Diabetes 19: 109–115
Levin SR, Karam JH, Hane S, Grodsky GM, Forsham PH (1971) Enhancement of arginine-induced insulin secretion by prior administration of glucose. Diabetes 20: 171–176
Raptis S, Dollinger HC, Schroeder KE, Schleyer M, Rotherbuchner G, Pfeiffer EF (1973) Differences in insulin, growth hormone and pancreatic enzyme secretion after intravenous and intraduodenal administration of mixed amino acids in man. New Engl J Med 288: 1199–1202
Swislocki ALM, Donner CC, Fraze E, Chen YDI, Reaven GM (1987) Can insulin resistance exist as a primary defect in non-insulin-dependent Diabetes mellitus? J Clin Endocrinol Metab 64: 778–782
Wurtman RJ, Rose CM, Chou C, Larin FF (1968) Daily rhythms in the concentrations of various amino acids in human plasma. N Engl J Med 279: 171–175
Schauder P, Schroeder K, Langenbeck U (1984) Serum branched chain amino and keto acid response to a protein rich meal in man. Ann Nutr Metab 28: 350–356
Thomas FR, Sinar D, Mazzaferri EL, Cataland S, Mekhjian HS, Caldwell JH, Sromkes X (1978) Selective release of gastric inhibitory polypeptide by intraduodenal amino acid perfusion in man. Gastroenterol 74: 1261–1265
Yovos JG, O'Dorisio TM, Pappas TN, Cataland S, Thomas FB, Mekhjian H, Carey LC (1982) Effects of amino acids and gastric inhibitory polypeptide on insulin release in dogs. Am J Physiol 242: E53-E58
Pederson RA, Brown JC (1978) Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinol 103: 610–615
Rehfeld JF, Stadil F (1973) The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. J Clin Invest 52: 1415–1426
Fujimoto WY, Williams RH, Ensinck JW (1979) Gastric inhibitory polypeptide (GIP) and cholecystokinin, and secretin effects on insulin and glucagon secretion by islet cultures. Proc Soc Exp Biol Med 160: 349–353
Ahren B, Hedner P, Lundquist I (1983) Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice. Acta Endocrinol 102: 96–102
Nauck M, Reimers J, Ebert R, Cantor P, Creutzfeldt W (1987) Insulinotropic effect of endogenous and exogenous cholecystokinin in man. Diabetologia 30: 561 A
Creutzfeldt W, Reimers J, Nauck M, Ebert R, Cantor P (1987) CCK mediates increased exocrine but not endocrine secretion after intraduodenal phenylalanine. Dig Dis Sci 32: 1162 (A-5)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reimers, J., Nauck, M., Creutzfeldt, W. et al. Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man. Diabetologia 31, 271–280 (1988). https://doi.org/10.1007/BF00277407
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00277407